Xtandi 40 MG capsule 120S
Ended Awarded Last action
- Contract number
- SPE2DR26FRBX3
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $34,043
Award facts
- Contract value 100% obligated
- $34,042.72 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $34,042.72 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Xtandi 40 mg capsules (120-count units). The award, issued on January 28, 2026, with an ultimate completion date of January 29, 2026, utilizes a firm fixed-price contract structure without set-aside designation, indicating the vendor competed in unrestricted federal procurement. This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, which was established on November 13, 2025, with a $499.999 billion ceiling and extends through December 31, 2036.
The PPV-G GEN V program represents a $30.3 billion acquisition strategy through which the Defense Logistics Agency establishes multiple regional prime vendor contractors to supply pharmaceutical products and medical consumables to military healthcare facilities worldwide. DMS Pharmaceutical Group's role as a prime vendor contractor positions the company to fulfill recurring medical supply requirements across the Department of Defense's global healthcare operations. The company's extensive product portfolio encompasses branded and generic prescription medications, biologics, vaccines, and specialty pharmaceuticals including oncology treatments, with demonstrated performance across numerous delivery orders ranging significantly in value, establishing its capability to support diverse and specialized pharmaceutical requirements for federal military medical systems.
Quick answers
Who was awarded contract SPE2DR26FRBX3?
SPE2DR26FRBX3 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 28, 2026.
How much is contract SPE2DR26FRBX3 worth?
The government has obligated $34,043 on SPE2DR26FRBX3.
Is contract SPE2DR26FRBX3 an order under another contract?
Yes. SPE2DR26FRBX3 is a delivery order under SPE2DR25D9206, an indefinite delivery contract.
Was contract SPE2DR26FRBX3 competed?
The extent of competition for SPE2DR26FRBX3 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award